| Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
On June 17, 2024, Repare Therapeutics Inc., a corporation governed by the Business Corporations Act (Québec) (the “Company”), held its 2024 Annual Meeting of Shareholders (“Annual Meeting”), at which a quorum was present. At the Annual Meeting, the Company’s shareholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2024 (the “Proxy Statement”).
Proposal 1 - Election of Directors
Susan M. Molineaux, Ph.D. and Ann D. Rhoads were each elected to serve as a Class I director of the Company’s Board of Directors (the “Board”) until the 2027 Annual Meeting of Shareholders and until her successor is duly elected or until her earlier death, resignation or removal. The votes cast were as follows:
|
|
|
|
|
|
|
Nominee |
|
Votes For |
|
Votes Withheld |
|
Broker Non-Votes |
Susan M. Molineaux, Ph.D. |
|
32,268,618 |
|
14,009 |
|
3,714,807 |
Ann D. Rhoads |
|
31,692,160 |
|
590,467 |
|
3,714,807 |
Proposal 2 -Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers
The shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, by the following votes:
|
|
|
|
|
Votes For |
|
Votes Against |
|
Broker Non-Votes |
| 32,257,365 |
|
25,262 |
|
3,714,807 |
Proposal 3 - Appointment of Independent Registered Public Accounting Firm
The shareholders approved the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024, and authorized the Board to fix Ernst & Young LLP’s remuneration, by the following votes:
|
|
|
Votes For |
|
Votes Withheld |
| 35,992,711 |
|
4,723 |
